Combination therapy for treating cancer
AssigneeEpizyme, Inc.
InventorsHeike KEILHACK, Sarah Kathleen KNUTSON, Kevin Wayne KUNTZ
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
Claims24
-11. (canceled)
A method of treating cancer comprising administering to a subject in need thereof a therapeutically effective dose of a compound of Formula (IIa):
- or a pharmaceutically acceptable salt thereof and a therapeutically effective dose of rituximab, wherein
- each of Ra and Rb, independently, is H or C1-C6 alkyl;
- or Ra and Rb, together with the N atom to which they are attached, form a 4 to 7-membered heterocycloalkyl ring having 0 or 1 additional heteroatoms;
- wherein the C1-C6 alkyl or the 4 to 7-membered heterocycloalkyl ring are optionally substituted with one or more -Q3-T3, in which Q3 is a bond or unsubstituted or substituted C1-C3 alkyl linker, and T3 is H, halo, 4 to 7-membered heterocycloalkyl, C1-C3 alkyl, ORd, COORd, —S(O)2Rd, or —NRdRe, in which each of Rd and Re is independently H or C1-C6 alkyl, or -Q3T3 is oxo;
- R7 is isopropyl or C1-C6 alkyl, C3-C8 cycloalkyl, piperidinyl, tetrahydropyran, tetrahydro-2H-thiopyranyl,cyclopentyl, or cyclohexyl, or 4 to 12-membered heterocycloalkyl, each optionally substituted with one or more -Q5-T5, in which Q5 is a bond, C(O), C(O)NRk, NRkC(O), S(O)2, or C1-C3 alkyl linker, Rk being H or C1-C6 alkyl, and T5 is H, halo, C1-C6 alkyl, hydroxyl, cyano, C1-C6 alkoxyl, amino, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, C3-C8 cycloalkyl, C6-C10 aryl, 4 to 12-membered heterocycloalkyl, 5- or 6-membered heteroaryl, or S(O)qRq in which q is 0, 1, or 2 and Rq is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C10 aryl, 4 to 12-membered heterocycloalkyl, or 5- or 6-membered heteroaryl, and T5 is optionally substituted with one or more substituents selected from the group consisting of halo, C1-C6 alkyl, hydroxyl, cyano, C1-C6 alkoxyl, amino, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, C3-C8 cycloalkyl, C6-C10 aryl, 4 to 12-membered heterocycloalkyl, and 5- or 6-membered heteroaryl except when T5 is H, halo, hydroxyl, or cyano;
- or -Q5-T5 is oxo;
- and
- R8 is H, methyl, or ethyl;
- wherein the cancer is resistant or refractory to at least one prior therapy;
- and
- wherein the compound of Formula (IIa) and said rituximab are administered simultaneously or sequentially.
-27. (canceled)
-33. (canceled)
-37. (canceled)
A method of treating cancer comprising administering to a subject in need thereof a therapeutically effective dose of a compound of Formula (IIa):
- or a pharmaceutically acceptable salt thereof, a therapeutically effective dose of rituximab, and a therapeutically effective dose of lenalidomide, wherein
- each of Ra and Rb, independently, is H or C1-C6 alkyl;
- or Ra and Rb, together with the N atom to which they are attached, form a 4 to 7-membered heterocycloalkyl ring having 0 or 1 additional heteroatoms;
- wherein the C1-C6 alkyl or the 4 to 7-membered heterocycloalkyl ring are optionally substituted with one or more -Q3-T3, in which Q3 is a bond or unsubstituted or substituted C1-C3 alkyl linker, and T3 is H, halo, 4 to 7-membered heterocycloalkyl, C1-C3 alkyl, ORd, COORd, —S(O)2Rd, or —NRdRe, in which each of Rd and Re is independently H or C1-C6 alkyl, or -Q3T3 is oxo;
- R7 is isopropyl or C1-C6 alkyl, C3-C8 cycloalkyl, piperidinyl, tetrahydropyran, tetrahydro-2H-thiopyranyl,cyclopentyl, or cyclohexyl, or 4 to 12-membered heterocycloalkyl, each optionally substituted with one or more -Q5-T5, in which Q5 is a bond, C(O), C(O)NRk, NRkC(O), S(O)2, or C1-C3 alkyl linker, Rk being H or C1-C6 alkyl, and T5 is H, halo, C1-C6 alkyl, hydroxyl, cyano, C1-C6 alkoxyl, amino, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, C3-C8 cycloalkyl, C6-C10 aryl, 4 to 12-membered heterocycloalkyl, 5- or 6-membered heteroaryl, or S(O)qRq in which q is 0, 1, or 2 and Rq is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C10 aryl, 4 to 12-membered heterocycloalkyl, or 5- or 6-membered heteroaryl, and T5 is optionally substituted with one or more substituents selected from the group consisting of halo, C1-C6 alkyl, hydroxyl, cyano, C1-C6 alkoxyl, amino, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, C3-C8 cycloalkyl, C6-C10 aryl, 4 to 12-membered heterocycloalkyl, and 5- or 6-membered heteroaryl except when T5 is H, halo, hydroxyl, or cyano;
- or -Q5-T5 is oxo;
- and
- R8 is H, methyl, or ethyl;
- wherein the cancer is resistant or refractory to at least one prior therapy;
- and
- wherein the compound of Formula (IIa) and said rituximab and said lenalidomide are administered simultaneously or sequentially.
Dependencies are inferred from the claim text.